Abstract: The present disclosure relates to a serum exosomal SF3B4 marker composition for diagnosing early stage hepatocellular carcinoma for noninvasive in vitro diagnosis, wherein, by analyzing an expression level of SF3B4 in plasma proteins as well as expression of SF3B4 in exosomes present in sera of hepatocellular carcinoma patients, the possibility as the most suitable liquid biopsy marker was identified, and a new noninvasive biomarker with high diagnostic accuracy in early stage hepatocellular carcinoma for which no reliable biomarker exists at this present was discovered. As such, by using exosomes to identify cancer cell genomes and proteomes without biopsy, the exosomes are highly applicable in the future as a diagnostic biomarker that is useful in a disease group with a high risk in the biopsy such as hepatocellular carcinoma.

Abstract: The present disclosure relates to the use of genes whose expression or protein changes specifically to hepatocellular carcinoma as biomarkers for the detection and diagnosis of hepatocellular carcinoma, in which the biomarkers of the present disclosure, HMMR, NXPH4, PITX1, THBS4, and UBE2T, since they change their expression specifically to hepatocellular carcinoma, may be used as hepatocellular carcinoma-specific markers, and furthermore, these biomarkers may be used independently or in combination with AFP, or may be independently combined to make a more specific and accurate diagnosis of hepatocellular carcinoma.

Abstract: The present invention relates to novel markers for diagnosing brain disease caused by brain injury and the use thereof. More particularly, the present invention relates to novel diagnostic markers for brain disease caused by brain injury, which are identified by administering an MDMA drug, a diagnostic composition for brain disease caused by brain injury, a kit, a microarray, and a method for diagnosing brain disease caused by brain injury using the same, and relates to a method for screening a material for preventing or treating brain disease and a composition for preventing or treating brain disease caused by brain injury including the material. It was found that the expression amount of the marker genes of the present invention in tissues or cells of a patient with brain injury was over-expressed or under-expressed compared with that in normal tissues or cells.